anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A new pharmacologically effective substance (I) is obtd. by (a) subjecting the blossom of plants of the urtica family to dry-fermentation with regulated air circulation at 36-42 degrees C, until a grey-white covering of fungus is formed on the dried plants; (b) forming an aq. slurry from the fungus-covered dried plants, and distilling under atmos. pressure and in the presence of metallic Cu until the pH of the distillate is ca. 7; (c) keeping the distillate in an airtight vessel at room temp. until the pressure which initially dropped readjusts and the pH is ca. 4.5, and then carrying out a second distillation and collecting the blue-green first fraction of pH ca. 10; and (d) either (i) concg. this fraction in vacuo until a ppte. forms which is then filtered off and dried, or (ii) heating the fraction to 95 degrees C, removing the pptd. impurities, by filtration and then concg. to crystallise out (I). The crystals obtd. in this step (d(ii)) are colourless, melt at 138-139 degrees C and solns. in water have pH 4.5. (I) is esp. effective against hay fever (rhinitis anaphylartica) and attendant phenomena e.g., bronchial asthma, rhinitis, conjunctivitis, dermatitis, as well as against flu. When administered by i.m. injection, no side effects were observed. (I) can be used to immunise against hay fever of flu for periods of up to one year. When taken orally (I) increased oxygen absorption and muscular efficiency, and is effective against diabetes.
PURPOSE:To provide a troche containing ibuprofen singly or in combination with cyclodextrin and effective in mitigating the laryngeal inflammation and pain by the direct action to the oral mucosa and laryngeal mucosa. CONSTITUTION:The objective troche contains 10-50mg (preferably 5-30mg) of ibuprofen which is a non-steroidal analgesic anti-inflammatory agent and, as necessary, 2-10 pts.wt. (preferably 4-6 pts.wt.) of cyclodextrin based on 1 pt.wt. of ibuprofen. An excellent remedying effect can be attained in spite of low content of the drug component compared with a commercially available peroral drug and the troche has decreased stimulation.
INTRODUCTION: Balancing the prevention of thrombosis with bleeding risk when combining anticoagulants and platelet antagonists remains a concern among clinicians, particularly in patients with acute coronary syndrome (ACS) who are treated with potent antiplatelet therapy. This may be because the available antiplatelet and anticoagulants are unable to uncouple physiological hemostasis and pathological thrombosis. Therefore, their use is associated with an unavoidable elevated risk of bleeding.
AREAS COVERED: Evidence available from studies evaluating FXIa inhibitors and milvexian was collected from a selective literature search. In this review, the authors describe the potential role of FXI/XIa in experimental thrombosis, evidence for FXIa inhibition in the treatment of clinical thrombotic events, and highlight the current evidence supporting the role of milvexian, a novel FXIa inhibitor, in patients with ACS.
EXPERT OPINION: The ongoing LIBREXIA-ACS trial is a large-scale study currently investigating milvexian in patients with ACS. This study may support the proof of concept of differentiating physiological hemostasis and pathological thrombosis and achieving maximum antithrombotic efficacy with minimum bleeding risk when used on top of dual antiplatelet therapy with potent P2Y12 receptor blockers.
Drug-tolerant persisters (DTPs) are a rare subpopulation of cells within a tumor that can survive therapy through nongenetic adaptive mechanisms to develop relapse and repopulate the tumor following drug withdrawal. Using a cancer cell line with an engineered suicide switch to kill proliferating cells, we perform both genetic screens and compound screens to identify the inhibition of bromodomain and extraterminal domain (BET) proteins as a selective vulnerability of DTPs. BET inhibitors are especially detrimental to DTPs that have reentered the cell cycle (DTEPs) in a broad spectrum of cancer types. Mechanistically, BET inhibition induces lethal levels of ROS through the suppression of redox-regulating genes highly expressed in DTPs, including GPX2, ALDH3A1, and MGST1. In vivo BET inhibitor treatment delays tumor relapse in both melanoma and lung cancer. Our study suggests that combining standard of care therapy with BET inhibitors to eliminate residual persister cells is a promising therapeutic strategy.
Systems and methods of enabling a medical device for operation and billing a medical procedure performed with a medical device. A medical procedure barcode is purchased through a user interface executing on a server. The server updates a medical procedure database to indicate that the purchased medical procedure barcode is valid. The medical procedure barcode is read by a barcode reader, and the medical procedure database is queried to determine if the read medical procedure barcode is valid. A medical device is enabled for use by a medical procedure service provider if the medical procedure barcode is valid, such that the medical procedure may be performed using the enabled medical device. The medical procedure database is updated to indicate that the medical procedure barcode has been redeemed by the medical procedure service provider. The server transmits payments to the medical procedure service provider for the redeemed medical procedure barcode.
The present invention provides an application of an SP peptide or a derivative thereof in preparing drugs for preventing or treating asthma. The peptide or the derivative thereof is the SP peptide shown in a formula (I) or a pharmaceutically acceptable salt or ester thereof. The present invention also provides a method for treating asthma. The method comprises: treating a patient with a drug containing a therapeutically effective amount of the peptide or the derivative thereof. It proves through researches of the present invention that, the peptide or the derivative thereof can effectively improve pathological symptoms of asthma, especially the pathological symptoms of allergic asthma. In the formula (I), Xaa1 is deletion, Ala, Gly, Val, Leu or Ile; Xaa2 is Thr or Ser; Xaa3 is Tyr, Phe or Trp; and Xaa4 is deletion, Ala, Gly, Val, Leu, Ile or Pro.
The invention provides a composition which is effective in the prevention or delay of the onset of side effects associated with alcohol consumption or the reduction or alleviation of those effects. The composition of the invention includes activated charcoal and limestone, optionally activated limestone. Optionally, the composition of the invention also includes vitamin B1 and/or other agents such as fatigue relieving agents. Preferably, the composition of the invention is provided in the form of tablets or powder encapsulated in a gelatin capsule. The composition of the invention is provided in pre-dosed quantities varying from between about 100 and 500 milligrams per dose. The invention also provides a method of reducing or alleviating the deleterious effects associated with alcohol consumption. The method includes administration, preferably multiple administration at regularly spaced intervals before, during, and after alcohol consumption of a composition containing activated charcoal and activated limestone.
OBJECTIVE: To investigate endothelial cell loss (ECL) associated with Descemet membrane endothelial keratoplasty (DMEK) donor tissues preloaded in the DMEK RAPID transport system after 1 and 5 days and to compare prestamping with 2 different F-mark inks.
METHODS: DMEK donor tissues were stripped, marked with gentian violet dye applied as an F-mark, trephined, stained with trypan blue, and then preloaded into the DMEK RAPID transport system by an eye bank technician. Preloaded DMEK tissues were then unfolded and stained with calcein AM after 1 or 5 days of storage. Tissues were imaged, analyzed for total tissue ECL, and immunostained for corneal endothelium markers zonular occludens-1 and xCD166. Additionally, ECL and the intensity of an F-mark caused by 2 different inks were quantified.
RESULTS: Preloaded DMEK tissues displayed an average ECL of 11.9% ± 4.5% (n = 8) at 1 day and 9.9% ± 4.2% (n = 9) at 5 days. No difference was found between the 2 groups. Zonular occludens-1 and activated leukocyte cell adhesion molecule (ALCAM; also know as CD166) staining showed that the corneal endothelial monolayer remained intact on preloaded tissues. On 5-day preloaded DMEK tissues, the average ECL and mean grayscale caused by the Keir Surgical ink F-mark and the Cardinal Health ink F-mark were 4.3% ± 0.8% and 158.5 ± 13.9% and 5.0% ± 1.1% and 142.9% ± 20.0%, respectively. No difference was found between the F-mark inks.
CONCLUSION: Preloaded DMEK donor tissues resulted in an acceptable ECL range after 1 and 5 days of storage and were deemed suitable for transplantation. Both F-mark inks are acceptable for prestamping preloaded DMEK tissues prior to surgical transplantation with comparable ECL and intensities.
Patients undergo OGTT and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to HCT. Patients then undergo repeat OGTT and a 2-step euglycemic hyperinsulinemic clamp procedure once after HCT between days 90-100.
Canada's children are falling behind. One in 4 are overweight or obese and more than 1 in 3 have factors that put them at risk for cardiovascular disease as adults. Children from low income families are 70% more likely to be overweight or obese. Research across disciplines has shown that early life nutrition has profound effects on childhood obesity, development, mental health, and lifetime success. Optimizing early life nutrition to reduce inequalities in childhood obesity and its consequences is a promising approach. Through this application, we will be using a longitudinal factorial design within an ongoing cohort study(TARGet Kids!). The longitudinal factorial design involves randomizing the same children to multiple interventions, providing the opportunity to evaluate the effect of individual interventions as well as the multiplicative effects of a combination of interventions over time. This design increases the feasibility and lowers the cost relative to conducting 2 separate trials. This will be a pragmatic, randomized, longitudinal factorial Trials within Cohorts (TwiCs) clinical trial. This study will be a direct comparison of two primary healthcare interventions provided randomly at the individual level: 1) Lactation Consultant (LC) support vs. usual care; 2) Childcare Navigator (CN) support vs. usual care.
PURPOSE:To obtain a cosmetic having cleaning effect, peeling effect or massaging effect, by compounding porous spherical cellulose having specific particle diameter and bulk density. CONSTITUTION:A porous spherical cellulose having particle diameter of 0.1-1.0mm and bulk density of 0.1-0.7g/cc is compounded to a cosmetic (excluding powdery cosmetic) such as face lotion, creams and packs in an amount of 0.1-50wt.%, preferably 1-20wt.% based on whole cosmetic composition. Stains in pores, aged horny layer and sebum, etc., resistant to be removed with soap alone can be removed by the above fine particles having moderate hardness and elasticity. The circulation of blood can be improved and the metabolism of skin can be promoted by the massaging effect of the particles. Accordingly, the cosmetic is expected to have preventive and remedying effect to spots. The cosmetic is safe and can be produced by utilizing easily available natural material.
Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis.”

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C. difficile colitis.
The invention discloses Tibetan perfume with rose fragrance and a preparation method thereof. The Tibetan perfume comprises the following components in parts by weight: 0.5-3 parts of Chinese eaglewood essential oil, 0.5-4 parts of rhododendron parvifolium essential oil, 8-13 parts of roses and 30-150 parts of insipid dialdehyde ethanol. The Tibetan perfume prepared by adopting the essential oil extracted from the medicines to coordinate with the insipid dialdehyde ethanol has certain health efficacy on human bodies. After the essential oil is dissolved by the insipid dialdehyde ethanol, the shelf life can be greatly lengthened, and the fragrance can be emitted quickly. The shelf life of the prepared perfume can be as long as two years, the fragrance retaining time is long, and the taste is special. The roses also have the functions of whitening and moisturizing.
Incentives of abstinence will be given to those who self-report abstinence for the past 7 days and pass the 3-month biochemical validation (Group B-Q), but they will not be informed about the incentive at the 1-week and 1-month follow-up. Those who have not quitted at 3 months (Group B-N) or those self-reported quitters who refuse to participate in the biochemical validation will be informed that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
BACKGROUND AND STUDY AIMS: The integration of traditional Chinese medicine and Western medicine holds promise for the treatment of gastrointestinal disorders, which are influenced by intestinal microbiota and metabolites. This study reports a possible mechanism for the combination of Simo Decoction and Golden Bifid in functional dyspepsia (FD) by regulating intestinal microbiota and short-chain fatty acids (SCFAs).
PATIENTS AND METHODS: A mouse model of food stagnation was constructed and treated with Simo Decoction combined with different concentrations of Golden Bifid. Meta-genomics sequencing was conducted to analyze the cecum contents of the mice. Following analyses of the composition and abundance of intestinal microbiota, gas chromatography-mass spectrometry was performed to measure SCFAs in the colonic content of mice. Finally, ELISA was utilized to determine the levels of pro-inflammatory factors in the duodenal mucosa of mice and the infiltration of eosinophils in the duodenum was observed by immunohistochemical staining.
RESULTS: Combination of Simo Decoction and Golden Bifid more significantly alleviated dyspepsia in mice with food stagnation compared with Simo Decoction alone. The optimal ratio of combined treatment was 0.0075 mL/g (body weight) Simo Decoction and 0.0032 mg/g (body weight) Golden Bifid. The combined treatment increased the abundance of Bifidobacterium and Bacteroides in the intestine. The levels of SCFAs in the colonic contents of mice were increased after the combined treatment, contributing to diminished pro-inflammatory factors in the duodenal mucosa and reduced eosinophil infiltration.
CONCLUSION: Combination of Simo Decoction and Golden Bifid increases the abundance of Bacteroides and Bifidobacterium and promotes the production of SCFAs, which is instrumental for alleviation of FD.
Given the relatively low incidence, high prehospital death rate, substantial geographical differences, and complex disease origin (combination of genetic and environmental risk factors), epidemiologic research on subarachnoid hemorrhage (SAH) and its risk factors is challenging. In practice, we are more or less forced to exploit compromised study designs and nonrepresentative data in such circumstances where it is almost impossible to gather comprehensive data through an optimal design. For example, hospital-based patient cohorts, administrative data repositories, and short-term population-based studies from small geographical regions are often used to research the incidence, case fatality, and risk factors of SAH, regardless of their inherent and self-evident limitations. Since studies on the epidemiology of SAH focus largely on identifying possible risk factors that could aid in disease diagnostics, treatment, and prevention, we aimed to review recent evidence on modifiable risk factors for SAH. In this context, we also try to explain the methodological reasons behind some of the conflicting results and to discuss the primary strengths and limitations of different study designs used in the field of SAH epidemiology. Based on our findings, smoking, high blood pressure, and possibly low physical activity are the only risk factors with high-quality evidence supporting their causal role in SAH. In addition, since all 3 commonly used study designs in SAH epidemiology, namely, hospital-based, population-based, and administrative register-based studies, have their own strengths and limitations, the most robust risk factor estimates and other epidemiologic measures of SAH can likely be established by combining various overlapping and high-quality sources of information in the future.
Treatment with nasal solution of CYR-064 twice a day for 24 weeks. CYR-064 will be self-administered by patients.
The main goal of the Boston University's TIPS II project is to examine differences in Alzheimer's disease (AD) illness perceptions between African Americans and Whites in order to better understand attitudes and beliefs and to develop more culturally sensitive health services for AD. This 30-minute telephone survey will include a total of 140 first-degree relatives and caregivers of people with AD, as well as a comparison group of 70 adults without family history. The researchers will assess 1) beliefs about AD; 2) the perceived threat it poses; 3) sources of information about AD; 4) knowledge of basic facts about AD; 5) appraisal of AD treatments; and 6) intentions regarding current and emerging care options. Based on preliminary data, this study hypothesize that, as compared to Whites, African Americans will report lower levels of perceived threat, fewer sources of information, less awareness of facts, and less interest in care options. Focus group interviews with African American participants will help interpret study findings and inform recommendations for health education interventions.

Findings will inform the development of a set of recommendations for AD health educators that will help them tailor their interventions to African Americans. Such educational programs promote increased use of assessment, treatment, and caregiver assistance services. Results will also be used as pilot data in a proposal for a national survey of caregivers and relatives. This program of research will address a growing need for increased understanding of beliefs, knowledge, and intentions regarding AD. A total of 210 participants are being sought (105 African Americans, and 105 Whites). Participants who complete the survey will be given a $10.00 check, plus informational brochures on AD and the latest newsletter from the Boston University Alzheimer's Disease Center.
Endotracheal tubes (ETT) are secured during surgery and ICU care so that they are not accidentally removed from the airway. The position of the tip of the ETT is important and must not vary much within the trachea. The standard technique for securing an ETT is to use tape to attach it to the upper lip and face. The technique is cheap and simple, but suffers from certain drawbacks. First, the upper lip is mobile and thus even when well secured, the tube can move within the trachea due to this mobility. Second, conditions on the face such as sweating, drooling, facial hair, skin flaking or breakdown, all interfere with the ability of the tape to adhere, thus reducing its efficacy. Furthermore, the tape itself can irritate and or injure the facial skin. The adhesive irritates skin and certain patients are allergic to these substances. Also, removing the tape can physically damage the skin, especially if the skin is vulnerable to sheer forces (such as elderly patients or patients on systemic steroids).

Patients that are intubated often need a bite block or bite guard inserted into their mouths. This serves two main purposes: 1) to prevent the patient from biting the ETT and occluding airflow, 2) to prevent the patient from biting their tongue, cheek, or lips causing injury. Furthermore, endoscopic procedures are often performed on intubated patients and thus a bite block is needed to protect the delicate instrument from being bitten and damaged. For these reasons, many providers will insert bite blocks into the mouths of intubated patients. Many such devices exist on the market, but the most commonly used is the Guedel oral airway. This device is actually designed to increase airway patency during mask ventilation, and long term use of this device as a bite block has been linked to numerous complications including: 1)tongue swelling, often compromising the airway patency, 2) tooth damage, and 3)lip injury. Because of these shortcomings, specific ETT bite blocks have been developed, and some of these even double as an ETT securing device. However, these are usually made of hard, stiff materials that in and of themselves can injure the delicate oral structures. In summation, no single device that both serves as an ergonomic ETT holder and bite block has been successfully developed and marketed, and therefore the standard of care remains tape plus an oral airway.

The Haider airway is a combination ETT holder-securing device and bite block. Made of soft silicone rubber, the device was engineered from the ground up to serve those purposes with safety and comfort in mind. The device is FDA approved and in a pre-marketing trials phase to determine the efficacy of the product in specific clinical scenarios. Our institution has been tasked with testing the device in clinical scenarios where tape + oral airway has been historically problematic. We plan to compare this new device to tape + oral airway, the current standard of care in neurosurgical patients in the supine position. We hypothesize the device will be superior to the standard of care in both efficacy and patient comfort.
A single injection of 100 microgram corifollitropin alfa. Oocyte retrieval on day five after corifollitropin alfa injection.
The present invention is a multifunctional nutrient supplement and a process for creating the supplement. The supplement comprises a mixture of lecithin,  ginkgo biloba  and wheat germ oil. The supplement is made with a five step formation process. The first step of the process uses CO 2  supercritical extraction to remove cholesterol, glyceride and fatty acids from an egg yolk. Wheat germ oil is then obtained from dried wheat germ using CO 2  supercritical extraction.  Gingko biloba  is then removed from  ginkgo  leaves using CO 2  supercritical extraction. The egg yolk/lecithin from the first extraction is then combined with the wheat germ oil from the second extraction. Ethanol is then added to the mixture of lecithin and wheat germ oil and low temperature vacuum distilled to create a lecithin and wheat germ oil mixture. The  ginkgo biloba  extract is then added to the lecithin/wheat germ oil mixture to create the nutrient supplement.
Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). They will be instructed to use the traditional Bass brushing technique, brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.